Oncology Dealmaking In The Wake Of Changing Regulatory And Reimbursement Decisions
This article was originally published in Start Up
Executive Summary
As big drugmakers move wholeheartedly into oncology, changing regulatory and reimbursement standards have dramatic implications for dealmaking - especially for smaller venture-backed start-ups who hope to sign lucrative alliances or M&A deals with deeper-pocketed partners.